Washington — According to a retrospective sub-study of the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT), there is no evidence that ICD benefit varies with time from myocardial infarction (MI) to device implantation. Accordingly, single lead ICD benefit is not restricted to patients with a remote MI (>18 months). The study, published in the March edition of HeartRhythm, the official journal of the Heart Rhythm Society, suggests that ICD therapy post-MI decreases the chances of SCD starting immediately after the post-infarct period of 0-40 days.
In SCD-HeFT, 2,521 patients across the U.S., Canada, and New Zealand were randomly assigned to single lead, shock-only ICD therapy, amiodarone or placebo (double blind). The trial analyzed the use of ICDs in patients who experienced MI, yet had no previous life-threatening arrhythmia. The purpose of the trial was to determine the efficacy of ICDs as a primary prevention therapy for patients with moderate heart failure. The trial found that ICD therapy significantly decreased the relative risk of mortality by 23 percent. i
This retrospective sub-study, led by Jonathan Piccini, MD, MHS, for the SCD-HeFT investigators, analyzed the outcomes of ICD therapy in post-MI patients to determine whether mortality benefit varied as a function of time. Data from 712 patients were analyzed and divided into tertiles based on the amount of time that had passed between the patients MI and the implantation of a single-lead ICD.
Analysis revealed that patients randomized to ICD therapy (vs. placebo) were less likely to experience SCD in all three groups: 6.2% versus 14.2% within the first 2.11 years, 5.8% versus 10.3% between 2.11 and 7.31 years, and 2.5% versus 17.4% over 7.31 years. A sensitivity analysis was also conducted and revealed that there was no evidence that ICD benefit varied between ICD implantation within the first 18 months or after.
“It is widely known that the risk of SCD is most common in people immediately following a heart attack, yet some evidence suggests that the benefits of ICD therapy may be restricted to those patients who are more than a year after their MI,” said Jonathan Piccini, MD, MHS, Duke University Medical Center and Duke Clinical Research Institute. “However, the SCD-HeFT results show that the benefit of single lead, conservatively programmed ICD therapy is not limited to those patients remote from a myocardial infarction. Ensuring that eligible patients receive primary prevention defibrillator therapy is likely to be more important than when the device is implanted, outside of 40 days.”
Although future, prospective trials must take place in order to determine the optimal time and programming for ICD implantation after MI, the SCD-HeFT analysis has shown there is no evidence that ICD benefit varied with time from MI to implantation. Therefore, ICD implantation, at least as implemented in SCD-HeFT, should not be restricted to patients with remote MI (> 18 months), as previously suggested. The differences in outcome between SCD-HeFT and prior studies are not clear but the use of a simpler more conservatively programmed ICD may be responsible.
There are also some important limitations to the SCD-HeFT analysis. Patients with MI, unstable angina, or coronary revascularization within the last 30 days were not eligible for enrollment in SCD-HeFT. Additionally, only 10% of the patients in the SCD-HeFT analysis were within 6 months of their most recent MI.
For more information about this study, please visit www.heartrhythmjournal.com.
About Heart Rhythm Society
The Heart Rhythm Society is the international leader in science, education and advocacy for cardiac arrhythmia professionals and patients, and the primary information resource on heart rhythm disorders. Its mission is to improve the care of patients by promoting research, education and optimal health care policies and standards. Incorporated in 1979 and based in Washington, DC, it has a membership of more than 5,300 heart rhythm professionals in more than 72 countries around the world. www.hrsonline.org
About HeartRhythm Journal
HeartRhythm provides rapid publication of the most important science developments in the field of arrhythmias and cardiovascular electrophysiology (EP). As the official journal of the Heart Rhythm Society, HeartRhythm publishes both basic and clinical subject matter of scientific excellence devoted to the EP of the heart and blood vessels, as well as therapy. The journal is the only EP publication serving the entire electrophysiology community from basic to clinical academic researchers, private practitioners, technicians, industry and trainees. HeartRhythm Journal has an impact factor of 4.559 (as of 2010) and ranks 11th out of 78 cardiovascular medicine journals worldwide by the Institute for Scientific Information, remaining the number one specialty journal in cardiology. It is also the official publication of the Cardiac Electrophysiology Society.
Contact: Kennesha Baldwin
Heart Rhythm Society